Fiscal Year (FY) 2024 Notice of Supplemental Funding Opportunity, 75010-75011 [2023-24125]
Download as PDF
<![CDATA[
75010
Federal Register / Vol. 88, No. 210 / Wednesday, November 1, 2023 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Drug
Discovery and Molecular Pharmacology.
Date: November 15, 2023.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jeffrey Smiley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6194,
MSC 7804, Bethesda, MD 20892, (301) 272–
4596, smileyja@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflicts: Auditory, Visual and Cognitive
Neuroscience.
Date: November 30, 2023.
Time: 11:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Alena Valeryevna
Savonenko, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 1009J, Bethesda, MD 20892 (301) 594–
3444, savonenkoa2@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; AREA/
REAP: Respiratory, Cardiac and Circulatory
Sciences.
Date: November 30, 2023.
Time: 1:00 p.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kirk E Dineley, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institute of
Health, 6701 Rockledge Drive, Room 806E,
Bethesda, MD 20892, (301) 867–5309,
dineleyke@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Skeletal Muscle and Exercise
Physiology/Musculoskeletal Rehabilitation
Sciences.
Date: December 5, 2023.
Time: 9:30 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Aftab A Ansari, Ph.D.,
Scientific Review, Officer Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4108,
MSC 7814, Bethesda, MD 20892, (301) 237–
9931, ansaria@csr.nih.gov.
VerDate Sep<11>2014
19:48 Oct 31, 2023
Jkt 262001
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Musculoskeletal, Dental and Oral
Sciences.
Date: December 6, 2023.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Chee Lim, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4128, Bethesda, MD 20892,
(301) 435–1850, limc4@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–21–
120: Fogarty Global Infectious Disease
Research Training Program.
Date: December 8, 2023.
Time: 10:00 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Dayadevi Jirage, Ph.D.,
Scientific Review, Officer Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4422,
Bethesda, MD 20892, (301) 867–5309,
jiragedb@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 26, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2023–24116 Filed 10–31–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Fiscal Year (FY) 2024 Notice of
Supplemental Funding Opportunity
Substance Abuse and Mental
Health Services Administration,
Department of Health and Human
Services (HHS).
ACTION: Notice of intent to award
supplemental funding.
AGENCY:
This notice is to inform the
public that the Substance Abuse and
Mental Health Services Administration
(SAMHSA) is supporting a supplement
in scope of the original award to the
Community-Based, Advocacy-Focused,
Data-Driven, Coalition-Building
Association (CADCA) recipient funded
in FY 2019 under the National Anti-
SUMMARY:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Drug Coalitions Training and Workforce
Development Grant Program (Short
Title: Coalitions Training Grant), Notice
of Funding Opportunity (NOFO) SP–19–
002. The recipient may receive up to
$562,500. The supplemental funding
will extend the project period by 10months until September 29, 2024 and
will: leverage existing resources and
conference support to expand
SAMHSA’s scope and capacity; and
provide training and technical
assistance to state and community
prevention leaders, including members
of anti-drug community coalitions from
around the country who are committed
to addressing the evolving needs of the
behavioral health field. The training and
workforce development activities
supported through this grant include
SAMHSA’s Prevention Day and
SAMHSA’s participation in the annual
National Leadership Forum and annual
Mid-Year Training Institute of CADCA.
FOR FURTHER INFORMATION CONTACT:
David Lamont Wilson, Public Health
Analyst, Substance Abuse and Mental
Health Services Administration, 5600
Fishers Lane, Rockville, MD 20857,
telephone 240–276–2588; email:
david.wilson@samhsa.hhs.gov.
SUPPLEMENTARY INFORMATION:
Funding Opportunity Title: FY 2019
National Anti-Drug Coalitions Training
and Workforce Development Grant
Program (Short Title: Coalitions
Training Grant), Notice of Funding
Opportunity SP–19–002.
Assistance Listing Number: 93.243.
Authority: The Coalitions Training
Grant is authorized under sections 509,
516 and 520A of the Public Health
Service Act, as amended.
Justification: Eligibility for this
supplemental funding is limited to
CADCA, which was funded in FY 2019
under the National Anti-Drug Coalitions
Training and Workforce Development
Grant Program (Short Title: Coalitions
Training Grant). CADCA is the only
national organization that provides
training and technical assistance
annually through a national leadership
conference for thousands of members of
community coalitions dedicated to
preventing substance use. CADCA is
currently the sole organization that
plays a major role in helping to
strengthen and develop the nation’s
prevention infrastructure of anti-drug
coalitions in support of ongoing
activities funded by SAMHSA’s priority
prevention grant programs. It is the only
identified organization that currently
meets this experience level and national
reach to over 5,000 identified anti-drug
coalitions across the country.
E:\FR\FM\01NON1.SGM
01NON1
Federal Register / Vol. 88, No. 210 / Wednesday, November 1, 2023 / Notices
This is not a formal request for
application. Assistance will only be
provided to Coalitions Training Grant
(CADCA) funded in FY 2019 based on
the receipt of a satisfactory application
and associated budget that is approved
by a review group.
Dated: October 27, 2023.
Ann Ferrero,
Public Health Analyst.
[FR Doc. 2023–24125 Filed 10–31–23; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs using Urine or Oral Fluid
(Mandatory Guidelines).
FOR FURTHER INFORMATION CONTACT:
Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
2600 (voice); Anastasia.Flanagan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: In
accordance with Section 9.19 of the
Mandatory Guidelines, a notice listing
all currently HHS-certified laboratories
and IITFs is published in the Federal
Register during the first week of each
month. If any laboratory or IITF
certification is suspended or revoked,
the laboratory or IITF will be omitted
from subsequent lists until such time as
it is restored to full certification under
the Mandatory Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/resources/drug-testing/
certified-lab-list.
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
19:48 Oct 31, 2023
Jkt 262001
The Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITFs)
currently certified to meet the standards
of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
of the laboratories currently certified to
meet the standards of the Mandatory
Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines using Oral
Fluid were first published in the
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020.
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71 and allowed urine
drug testing only. The Mandatory
Guidelines using Urine have since been
revised, and new Mandatory Guidelines
allowing for oral fluid drug testing have
been published. The Mandatory
Guidelines require strict standards that
laboratories and IITFs must meet in
order to conduct drug and specimen
validity tests on specimens for federal
agencies. HHS does not allow IITFs to
conduct oral fluid testing.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines using Urine and/
or Oral Fluid. An HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that the test facility has met minimum
standards. HHS does not allow IITFs to
conduct oral fluid testing.
HHS-Certified Laboratories Approved
To Conduct Oral Fluid Drug Testing
In accordance with the Mandatory
Guidelines using Oral Fluid dated
October 25, 2019 (84 FR 57554), the
following HHS-certified laboratories
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
75011
meet the minimum standards to conduct
drug and specimen validity tests on oral
fluid specimens: At this time, there are
no laboratories certified to conduct drug
and specimen validity tests on oral fluid
specimens.
HHS-Certified Instrumented Initial
Testing Facilities Approved To Conduct
Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine dated January
23, 2017 (82 FR 7920), the following
HHS-certified IITFs meet the minimum
standards to conduct drug and specimen
validity tests on urine specimens:
Dynacare, 6628 50th Street NW,
Edmonton, AB Canada T6B 2N7, 780–
784–1190 (Formerly: GammaDynacare Medical Laboratories)
HHS-Certified Laboratories Approved
To Conduct Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine dated January
23, 2017 (82 FR 7920), the following
HHS-certified laboratories meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823 (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130 (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Clinical Reference Laboratory, Inc., 8433
Quivira Road, Lenexa, KS 66215–
2802, 800–445–6917
Desert Tox, LLC, 5425 E Bell Rd., Suite
125, Scottsdale, AZ 85254, 602–457–
5411/623–748–5045
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890
Dynacare,* 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630, (Formerly: GammaDynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609
Laboratory Corporation of America
Holdings, 7207 N Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 TW Alexander Drive,
E:\FR\FM\01NON1.SGM
01NON1
]]>Agencies
[Federal Register Volume 88, Number 210 (Wednesday, November 1, 2023)]
[Notices]
[Pages 75010-75011]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-24125]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Fiscal Year (FY) 2024 Notice of Supplemental Funding Opportunity
AGENCY: Substance Abuse and Mental Health Services Administration,
Department of Health and Human Services (HHS).
ACTION: Notice of intent to award supplemental funding.
-----------------------------------------------------------------------
SUMMARY: This notice is to inform the public that the Substance Abuse
and Mental Health Services Administration (SAMHSA) is supporting a
supplement in scope of the original award to the Community-Based,
Advocacy-Focused, Data-Driven, Coalition-Building Association (CADCA)
recipient funded in FY 2019 under the National Anti-Drug Coalitions
Training and Workforce Development Grant Program (Short Title:
Coalitions Training Grant), Notice of Funding Opportunity (NOFO) SP-19-
002. The recipient may receive up to $562,500. The supplemental funding
will extend the project period by 10-months until September 29, 2024
and will: leverage existing resources and conference support to expand
SAMHSA's scope and capacity; and provide training and technical
assistance to state and community prevention leaders, including members
of anti-drug community coalitions from around the country who are
committed to addressing the evolving needs of the behavioral health
field. The training and workforce development activities supported
through this grant include SAMHSA's Prevention Day and SAMHSA's
participation in the annual National Leadership Forum and annual Mid-
Year Training Institute of CADCA.
FOR FURTHER INFORMATION CONTACT: David Lamont Wilson, Public Health
Analyst, Substance Abuse and Mental Health Services Administration,
5600 Fishers Lane, Rockville, MD 20857, telephone 240-276-2588; email:
[email protected].
SUPPLEMENTARY INFORMATION:
Funding Opportunity Title: FY 2019 National Anti-Drug Coalitions
Training and Workforce Development Grant Program (Short Title:
Coalitions Training Grant), Notice of Funding Opportunity SP-19-002.
Assistance Listing Number: 93.243.
Authority: The Coalitions Training Grant is authorized under
sections 509, 516 and 520A of the Public Health Service Act, as
amended.
Justification: Eligibility for this supplemental funding is limited
to CADCA, which was funded in FY 2019 under the National Anti-Drug
Coalitions Training and Workforce Development Grant Program (Short
Title: Coalitions Training Grant). CADCA is the only national
organization that provides training and technical assistance annually
through a national leadership conference for thousands of members of
community coalitions dedicated to preventing substance use. CADCA is
currently the sole organization that plays a major role in helping to
strengthen and develop the nation's prevention infrastructure of anti-
drug coalitions in support of ongoing activities funded by SAMHSA's
priority prevention grant programs. It is the only identified
organization that currently meets this experience level and national
reach to over 5,000 identified anti-drug coalitions across the country.
[[Page 75011]]
This is not a formal request for application. Assistance will only
be provided to Coalitions Training Grant (CADCA) funded in FY 2019
based on the receipt of a satisfactory application and associated
budget that is approved by a review group.
Dated: October 27, 2023.
Ann Ferrero,
Public Health Analyst.
[FR Doc. 2023-24125 Filed 10-31-23; 8:45 am]
BILLING CODE 4162-20-P
